Business
Regeneron Reports Third Quarter 2021 Financial and Operating Results
TARRYTOWN, N.Y., Nov. 4, 2021 /PRNewswire/ -- Third quarter 2021 revenues increased 51% to $3.45 billion versus third quarter 2020 including $804 million
About this update from Regeneron Pharmaceuticals, Inc.
[{"type":"text","content":"TARRYTOWN, N.Y., Nov. 4, 2021 /PRNewswire/ -- \nThird quarter 2021 revenues increased 51% to $3.45 billion versus third quarter 2020 including $804 million attributable to REGEN-COV®(2) Third quarter 2021 EYLEA® U.S. net sales increased 12% versus third quarter 2020 to $1.47 billion Third quarter 2021 Dupixent® global net sales(3), which are recorded by Sanofi, increased 55% to $1.66 billion versus third quarter 2020 Third quarter 2021 GAAP diluted EPS was $14.33 and non-GAAP diluted EPS(1) was $15.37 Positive results reported from four Phase 3 Dupixent studies; FDA expanded approval of Dupixent to include children aged 6 to 11 years with asthmaRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2021 and provided a business update. \n\"Regeneron had another strong quarter of core business growth, with EYLEA and Dupixent reaching more patients than ever and progress made across our diverse pipeline,\" said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron. \"We secured a new U.S. government supply agreement and are delivering an additional 1.4 million doses of REGEN-COV. Our Biologics License Application for REGEN-COV as treatment and prophylaxis was accepted by the FDA for priority review, with a mid-April 2022 action date. During the third quarter, we announced positive data from Phase 3 trials of Dupixent in chronic spontaneous urticaria and pediatric atopic dermatitis. We also recently announced positive data from Phase 3 trials of Dupixent in eosinophilic esophagitis and prurigo nodularis, and that the FDA approval in pediatric asthma was extended to children as young as six. Finally, our abstracts that will be released today for the American Society of Hematology (ASH) Annual Meeting highlight programs across the hematology portfolio, including our BCMA and C5 antibodies.\" \nFinancial Highlights \n($ in millions, except per share data)\nQ3 2021\nQ3 2020\n% Change\nTotal revenues\n$\n3,453\n$\n2,294\n51%\nGAAP net income\n$\n1,632\n$\n842\n94%\nGAAP net income per share - diluted\n$\n14.33\n$\n7.39\n94%\nNon-GAAP net income(1)\n$\n1,773\n$\n961\n84%\nNon-GAAP net income per share - diluted(1)\n$\n15.37\n$\n8.36\n84%\n\"Regeneron performed extremely well in the third quarter with strong top- and bottom-line growth driven by an increasin...